Alcon Completes Acquisition of DUREZOL and ZYCLORIN From Sirion
Alcon will immediately assume all marketing, promotion and sales of DUREZOL. management said that it is continuing to evaluate options to acquire ZIRGAN, an antiviral recently approved by the FDA for the treatment of acute herpetic keratitis (corneal ulcers).
DUREZOL emulsion is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery and received approval from the US Food and Drug Administration (FDA) in 2008.
Currently under clinical investigation to treat dry eye and other ocular surface diseases, ZYCLORIN is a topical ophthalmic immunomodulator and immunosuppressive agent.
Stuart Raetzman, vice president of global marketing and area president for the US at Alcon, said: “This acquisition reinforces our ability to drive growth in the near-term with the acquisition of DUREZOL and add products to our long-term research pipeline with ZYCLORIN. Durezol’s unique capability to effectively and quickly treat both inflammation and pain following ocular surgery makes it a great fit for Alcon’s leading product portfolio.”
Will this acquisition benefit Alcon?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.